Matinas BioPharma downgraded by Piper Sandler
$MTNB
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral
Save time and jump to the most important pieces.
SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
3 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
3 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn
NEW YORK, Jan. 24, 2025 /PRNewswire/ - 111 Equity Group, LLC ("111 Equity") and its principal filed a Schedule 13D with the Securities and Exchange Commission ("SEC") to disclose that 111 Equity and its principal have collectively accumulated a 5.17% stock ownership stake in Matinas Biopharma Holdings, Inc. (NYSE:MTNB) ("MTNB") as of January 2, 2025. Since this filing, the principal of 111 Equity bought more shares to increase 111 Equity's and the principal's collective ownership in MTNB as 111 Equity believes MTNB provides an opportunity for shareholders to enhance shareholder value. MTNB announced the start of a strategic review in late October 2024. 111 Equity believes there are avenues t
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer. Mr. Hoover's role will include business and corporate development, strategic planning, licensing, and alliance management. "We are excited to have Thomas join our executive leadership team in this critical role during this transformational time for our Company," commented Jerome D.
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral